The ability to individualize medication therapy for cancer patients has significantly advanced in recent years and continues to expand into new areas of practice. One of these areas is pharmacogenetic testing, which evaluates inherited genetic differences in drug metabolic pathways that can affect individual responses to drugs both in terms of therapeutic effect as well as adverse effects. While more than 130 FDA-approved medications have references to pharmacogenetic testing in their package insert, until recently there has been little guidance on how to apply this information in the clinic setting. The Clinical Pharmacogenetic Implementation Consortium (CPIC, epicpgx.org) was established to provide clinical practice guidelines for meaningful prescribing decisions of specific drug/gene pairs. Since the development of the CPIC guidelines, there are currently specific dosing recommendations for 35 medications. However, the majority of pharmacogenetic testing continues to be done in the academic setting—even with CPIC's supporting data, few community cancer programs are performing this form of personalized medicine.